Analysis of migraine characteristics in postmenopausal women
https://doi.org/10.14412/2074-2711-2024-1S-38-44
Abstract
Objective: to identify characteristics of migraine in women in postmenopause (PM) by analyzing the frequency, duration and intensity of migraine attacks, assessment of quality of life, anxiety, depression and sleep disturbances in patients in the reproductive phase (RP) and in the PM.
Material and methods. The study comprised 60 migraine patients (30 patients in the RP, 30 patients in the PM). During the personal interview, age, migraine type, frequency and duration of attacks and headache (HA) intensity on the visual analogue scale (VAS) were recorded. The patients then completed the questionnaires: HIT-6, MIBS-4, HURT, Migraine- ACT, MIDAS, SF-36, HADS, ISQ. The statistical analysis was performed in Microsoft Office Excel 2021.
Results. The risk of high intensity HA (≥8 points on the VAS) was significantly higher in patients in the PM than in patients in the RP [p<0.05; relative risk (RR) 1.77]. The risk of necessity of a revision of therapy of attacks was higher in the PM than in the RP (p=0.004; RR=2.2). The risk of insomnia was higher in the PM than in the RP (p=0.004; RR=4.67). The risk of severe headache impact (HIT-6) and high migraine burden (MIBS-4) was higher in patients in the PM than in the RP (ORHIT6=1.7; ORMIBS4=1.78). All indicators of SF-36 quality of life questionnaire were significantly lower in patients in the PM group than in the RP group (p<0.05). The risk of subclinical and clinical anxiety (p<0.05; RR=4.33) and depression (p<0.05; RR=2.75) was significantly higher in the PM than in the RP.
Conclusion. Migraine attacks in women in the PM are more intense than in women in the RP, quality of life is lower, and revision of therapy for attacks is required more frequently. Patients with migraine in the PM are more likely to suffer from anxiety, depression and insomnia. Further research is needed to determine the causes of the observed phenomena and to develop migraine therapy in patients in the PM.
Keywords
About the Authors
D. A. Klimentova
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Diana Andreevna Klimentova
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
O. V. Kosivtsova
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
A. V. Sergeev
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
G. R. Tabeeva
Department of Nervous Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021
Competing Interests:
The investigation has not been sponsored. There are no conflicts of interest. The authors are solely responsible for submitting the final version of the manuscript for publication. All the authors have participated in developing the concept of the article and in writing the manuscript. The final version of the manuscript has been approved by all the authors.
References
1. Ripa P, Ornello R, Degan D, et al. Migraine in menopausal women: a systematic review. Int J Womens Health. 2015 Aug 20;7:773-82. doi: 10.2147/IJWH.S70073
2. Pavlovic JM. The impact of midlife on migraine in women: summary of current views. Womens Midlife Health. 2020 Oct 6;6:11. doi: 10.1186/s40695-020-00059-8
3. Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas. 1993 Jul;17(1):31-7. doi: 10.1016/0378-5122(93)90121-w
4. Karpova MI, Zariada AA, Dolgushina VF, et al. Migraine in women: clinical and therapeutical aspects. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(3):98-107. doi: 10.17116/jnevro201911903198 (In Russ.).
5. Makita K, Inagaki M, Kitamura S, Tatsuoka Y. Changes in migraine before and after menopause in Japanese climacteric women. Cephalalgia. 2017 Oct;37(11):1088-92. doi: 10.1177/0333102416653234. Epub 2016 Jun 2.
6. Cupini LM, Matteis M, Troisi E, et al. Sex-hormone-related events in migrainous females. A clinical comparative study between migraine with aura and migraine without aura. Cephalalgia. 1995 Apr;15(2):140-4. doi: 10.1046/j.1468-2982.1995.015002140.x
7. Ornello R, Caponnetto V, Frattale I, Sacco S. Patterns of Migraine in Postmenopausal Women: A Systematic Review. Neuropsychiatr Dis Treat. 2021 Mar 19;17:859-71. doi: 10.2147/NDT.S285863
8. Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and Menopause Are Associated With High Frequency Headache in Women With Migraine: Results of the American Migraine Prevalence and Prevention Study. Headache. 2016 Feb;56(2):292-305. doi: 10.1111/head.12763. Epub 2016 Jan 21.
9. Saffari TM, Kavanagh K, Ormseth B, et al. Severe obesity is associated with increased migraine severity and frequency: A retrospective cohort study. J Clin Neurosci. 2023 Sep;115:8-13. doi: 10.1016/j.jocn.2023.07.007. Epub 2023 Jul 14.
10. MacGregor EA, Barnes D. Migraine in a specialist menopause clinic. Climacteric. 1999 Sep;2(3):218-23. doi: 10.3109/13697139909038065
11. Mattsson P. Hormonal factors in migraine: a population-based study of women aged 40 to 74 years. Headache. 2003 Jan;43(1):27-35. doi: 10.1046/j.1526-4610.2003.03005.x
12. Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. Headache. 2003 May;43(5):470-8. doi: 10.1046/j.1526-4610.2003.03092.x
13. Carturan P, Scorcine C, Fragoso YD. Migraine in the post-menopausal period is associated with higher levels of mood disorders, disability, and more menopausal symptoms. Arq Neuropsiquiatr. 2016 Dec;74(12):999-1002. doi: 10.1590/0004-282X20160153
14. Luo J. Association between migraine and anxiety symptoms: Results from the study of women's health across the nation. J Affect Disord. 2021 Dec 1;295:1229-33. doi: 10.1016/j.jad.2021.09.036. Epub 2021 Sep 17.
15. Babateen O, Althobaiti FS, Alhazmi MA, et al. Association of Migraine Headache With Depression, Anxiety, and Stress in the Population of Makkah City, Saudi Arabia: A Cross-Sectional Study. Cureus. 2023 May 31;15(5):e39788. doi: 10.7759/cureus.39788
16. Alwhaibi M, Balkhi B, AlRuthia Y. Anxiety and depression and health-related quality of life among adults with migraine: a National Population-Based Study. Front Public Health. 2023 Oct 4;11:1241800. doi: 10.3389/fpubh.2023.1241800
17. Nesbitt AD. Comorbidities of migraine: Sleep disorders. Handb Clin Neurol. 2024;199:525-34. doi: 10.1016/B978-0-12-823357-3.00020-3
18. Chu S, Wu Z, Wu Z, et al. Association Between Insomnia and Migraine Risk: A Case-Control and Bidirectional Mendelian Randomization Study. Pharmgenomics Pers Med. 2021 Aug 13;14:971-6. doi: 10.2147/PGPM.S305780
19. Lee W, Shin HJ, Min IK, et al. Shared comorbidity of depression, migraine, insomnia, and fibromyalgia in a population-based sample. J Affect Disord. 2024 Jun 1;354:619-26. doi: 10.1016/j.jad.2024.03.077. Epub 2024 Mar 15.
20. Yoo A, Vgontzas A, Chung J, et al. The association between multidimensional sleep health and migraine burden among patients with episodic migraine. J Clin Sleep Med. 2023 Feb 1;19(2):309-17. doi: 10.5664/jcsm.10320
21. Salari N, Hasheminezhad R, Hosseinian-Far A, et al. Global prevalence of sleep disorders during menopause: a meta-analysis. Sleep Breath. 2023 Oct;27(5):1883-97. doi: 10.1007/s11325-023-02793-5. Epub 2023 Mar 9.
22. Hachul H, Hachul de Campos B, Lucena L, Tufik S. Sleep During Menopause. Sleep Med Clin. 2023 Dec;18(4):423-33. doi: 10.1016/j.jsmc.2023.06.004. Epub 2023 Jul 16.
23. Tasnim S, Nyholt DR. Migraine and thyroid dysfunction: Co-occurrence, shared genes and biological mechanisms. Eur J Neurol. 2023 Jun;30(6):1815-27. doi: 10.1111/ene.15753. Epub 2023 Mar 9.
24. Dev P, Favas TT, Jaiswal R, et al. The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebocontrolled trial. Cephalalgia. 2023 Oct;43(10):3331024231182684. doi: 10.1177/03331024231182684
25. Faubion SS, Smith T, Thielen J, et al. Association of Migraine and Vasomotor Symptoms. Mayo Clin Proc. 2023 May;98(5):701-12. doi: 10.1016/j.may-ocp.2023.01.010
26. MacDonald CJ, El Fatouhi D, Madika AL, et al. Association of Migraine With Incident Hypertension After Menopause: A Longitudinal Cohort Study. Neurology. 2021 Jul 6;97(1):e34-e41. doi: 10.1212/WNL.0000000000011986. Epub 2021 Apr 21.
27. Godley F 3rd, Meitzen J, Nahman-Averbuch H, et al. How Sex Hormones Affect Migraine: An Interdisciplinary Preclinical Research Panel Review. J Pers Med. 2024 Feb 7;14(2):184. doi: 10.3390/jpm14020184
28. Nappi RE, Tiranini L, Sacco S, et al. Role of Estrogens in Menstrual Migraine. Cells. 2022 Apr 15;11(8):1355. doi: 10.3390/cells11081355
29. Rustichelli C, Bellei E, Bergamini S, et al. Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study. Cephalalgia. 2020 Oct;40(12):1355-62. doi: 10.1177/0333102420937742. Epub 2020 Jun 26.
30. Mattsson P. Serum levels of androgens and migraine in postmenopausal women. Clin Sci (Lond). 2002 Nov;103(5):487-91. doi: 10.1042/cs1030487
31. Aegidius KL, Zwart JA, Hagen K, et al. Hormone replacement therapy and headache prevalence in postmenopausal women. The Head-HUNT study. Eur J Neurol. 2007 Jan;14(1):73-8. doi: 10.1111/j.1468-1331.2006.01557.x
Review
For citations:
Klimentova DA, Kosivtsova OV, Sergeev AV, Tabeeva GR. Analysis of migraine characteristics in postmenopausal women. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1S):38-44. (In Russ.) https://doi.org/10.14412/2074-2711-2024-1S-38-44
Views:
197
Email this article 